Rockwell Medical Inc (RMTI)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-09
$7.96-1.30%
Close 2026-09-09 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
Rockwell Medical aims to grow revenue to about $72.5 million in 2026. The company targets a gross margin near 20%. Management plans to achieve positive operating cash flow by year-end. Adjusted EBITDA is expected between $1 million and $2 million.
The company is loss-making with negative EPS expected in 2026. Recent revenue and gross margin progress is limited. Nasdaq delisting notice raises regulatory risk. The stock has fallen 37% from its high.
The price is about 39% above our fair value near $4.5. Analysts expect 10% revenue growth, but our model forecasts negative EPS in 2026. The market is stretched on growth expectations.
Breaks if: Adjusted EBITDA falls below $1 million in FY26
Target adjusted EBITDA between $1 million and $2 million for 2026 through operational improvements and cost control.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a speculative growth investment, as RMTI is working towards achieving positive cash flow and improving margins. The current thesis state reflects a cautious watch due to recent earnings misses and high near-term risk.
The market seems to have priced in a low expectations gap, indicating that RMTI is viewed as relatively cheap compared to its peers. However, the fundamentals suggest that the company is still loss-making, which may limit investor enthusiasm.
Management has shown stable priorities, focusing on achieving positive operating cash flow and improving gross margins. However, recent financial performance has been neutral, and there is a high probability of missing earnings expectations in the near term.
The long-term thesis hinges on RMTI's ability to meet its guidance and improve its financial metrics. Additionally, the performance of sector bellwethers and overall market conditions will influence RMTI's trajectory.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the outlook for positive cash flow in 2026. However, the company faces challenges in achieving its gross margin and adjusted EBITDA targets for 2026.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA improved from a loss of $0.7 million in first half 2025 to a loss of $0.4 million in first half 2026. Management reiterated a 2026 guidance range of $1 million to $2 million adjusted EBITDA, indicating progress but not yet delivering positive adjusted EBITDA.
“Adjusted EBITDA for the six months ended June 30, 2026 was ($0.4) million, an improvement compared to ($0.7) million for the same period in 2025”
“Adjusted EBITDA for the three months ended March 31, 2026 was ($0.3) million, an improvement over ($0.4) million for the same period in 2025”
“Rockwell Medical reiterates its 2026 annual guidance as follows: Adjusted EBITDA $1 million to $2 million”
Breaks if: Gross margin falls below 18% in FY26
Improve gross margin through lower manufacturing costs and higher volume to reach 18%-22% range in 2026.
Stated as a priority in 3 of last 3 quarters. Gross margin improved from 17% in 2026-Q1 to 18% in 2026-Q2, aligning with the reiterated 2026 guidance range of 18% to 22%. The trajectory is delivering incremental margin improvement consistent with management's stated goal.
“Gross Margin expanded to 18% primarily driven by lower manufacturing costs and higher volume”
“Gross margin for the three months ended March 31, 2026 was 17%, representing a slight improvement over 16% for the same period in 2025”
“Rockwell Medical reiterates its 2026 annual guidance as follows: Gross Margin 18% to 22%”
Breaks if: Operating cash flow remains negative through FY26
Focus on generating positive operating cash flow through growth, operational efficiencies, and cost savings in 2026.
Stated as a priority in 3 of last 3 quarters. Cash flow from operations improved from negative $167,000 in 2026-Q1 to positive $2.1 million in 2026-Q2. The company reiterated its 2026 guidance to achieve positive operating cash flow. The trajectory shows delivering progress toward this priority.
“On track to achieve full-year guidance with emphasis on top line growth, improving gross margins and positive cash flow”
“2026 guidance is centered around strengthening revenue, expanding gross margin, and generating positive Adjusted EBITDA and cash flow”
“Rockwell Medical reiterates its 2026 annual guidance as follows: Operating Cash Flow Positive”
Breaks if: Revenue falls below $70 million in FY26
Improve gross margin through lower manufacturing costs and higher volume to reach 18%-22% range in 2026.
Stated as a priority in 3 of last 3 quarters. Gross margin improved from 17% in 2026-Q1 to 18% in 2026-Q2, aligning with the reiterated 2026 guidance range of 18% to 22%. The trajectory is delivering incremental margin improvement consistent with management's stated goal.
“Gross Margin expanded to 18% primarily driven by lower manufacturing costs and higher volume”
“Gross margin for the three months ended March 31, 2026 was 17%, representing a slight improvement over 16% for the same period in 2025”
“Rockwell Medical reiterates its 2026 annual guidance as follows: Gross Margin 18% to 22%”
Over the next 1 to 3 years, RMTI's success will depend on its execution of financial goals amidst a challenging environment. Not investment advice.